Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 29339
Licensor is a leading fertility center that screens embryos for genetic disorders, such as cystic fibrosis and muscular dystrophy prior to implantation. The RGI hES lines include both normal cells and 88 cell lines identified as carrying a host of inherited genetic disease genes.
IPSCIO Record ID: 28404
By way of example, but not in limitation, Licensee shall have the right to use Licensed Technology within the Field for the following purposes to produce mammalian embryonic stem (ES) cells and to produce from those mammalian embryonic cells, differentiated cells for human therapeutic purposes or for commercial research purposes, including drug screening assays, and to produce pluripotent cells including ES cells, differentiated human cells for human diagnostic and therapeutic purposes and/or for commercial research purposes, including drug screening assays. b) A royalty bearing, twelve (12) month exclusive license in the Territory in the Field to expand in culture, prepare for sale, sell, offer for sale, import and export Act Animal Cell Lines. The twelve-month term of exclusivity granted to Licensee shall begin upon the date of the first sale of the Act Animal Cell Lines. Licensor and Licensee agree that after the twelve-month period of exclusivity has passed, Licensor and Licensee shall negotiate in good faith to establish reasonable minimum sales goals over reasonable evaluation periods in order to maintain Licenseeâ€™s exclusive rights hereunder. If Licensor fails to meet the minimum sales goals then Licenseeâ€™s exclusive rights shall revert to nonexclusive rights.
08/935,052 US 1997-09-22 CICM Cells and Non-Human Mammalian Embryos
6,235,970 2001-05-22 Prepared by Nuclear Transfer of a Proliferating Differentiated Cell or its Nucleus
09/828,876 US 2001-04-10 Cloning Using Donor Nuclei from Differentiated Fetal and Adult Cells UMASS
10/374,512 US 2003-02-27 Gynogenetic or Androgenetic Production of Pluripotent Cells and Cell Lines, and Use Thereof to Produce Differentiated Cells and Tissues
60/161,987 US 1999-10-28 Gynogenetic or Androgenetic Production of Pluripotent Cells and Cell Lines, and Use Thereof to Produce Differentiated Cells and Tissues
2,387,506 CA 2000-10-27 Gynogenetic or Androgenetic Production of Pluripotent Cells and Cell Lines, and Use Thereof to Produce Differentiated Cells and Tissues
Declared patent interferences
a) Patent Interference No. 104,746, involving U.S. Patent No. 5,945,577 and U.S. Patent Application No. 09/650,194.
b) Patent Interference No. 105,192, involving U.S. Patent No. 6,235,970 and U.S. Patent Application No. 09/989,126.
Potential patent interferences, verbally threatened to be filed against the following patents
IPSCIO Record ID: 28403
09/736,268 Transfer to De-Differentiate Recipient Cells
IPSCIO Record ID: 168
Company granted an exclusive license to use its â€œACTCellerateâ€ embryonic stem cell technology and a bank of over 140 diverse progenitor cell lines derived using that technology.
The licensed rights include pending patent applications, knowledge and the existing bank of cell lines. The licence is exclusive and worldwide for all commercial purposes, including the development of research products, and therapeutic and diagnostic products for human and veterinary use. Licensor has an option to reacquire rights to use the technology for the development of certain types of SCs for human therapeutic use in fields re-lated to its core business.
The technology allows the rapid isolation of novel, highly-purified embryonic progenitor cells. The progenitor cells are relatively easy to manufacture on a large scale and in a purified state, which may make it advantageous to work with these cells compared to the direct use of ESCs. These unique cell lines may have potential applications in research, drug discovery and human regenerative SC therapy.
103080-069-WO1 (PCT/US06/13519, filed on 4-11-06) Novel uses of cells with Prenatal Patterns of prenatal gene expression, published as WO2007/058671
103080-071-P61 (USSN 60/791,400, filed on Apr. 11, 2006) Methods to accelerate the isolation of novel cell strains from pluripotent ST
103080-071-P66 (USSN 60/850,294, filed on Oct. 6, 2006), Methods to accelerate the isolation ov novel cell strains from pluripotent stem cells
103080-071-P01 (USSN 11/604,047, filed on Nov. 21, 2006), Methods to accelerate the isolation of novel cell strains from pluripotent STE…
PCT is 103080-071-WO2 (PCT/US2006/45352, filed on Nov. 21, 2006), published as WO 2007/062198.
IPSCIO Record ID: 383576
Licensee agrees to mark, and to require Affiliates to mark, Products with the appropriate patent notice as approved by Licensors, when appropriate.
Technology shall mean the information, manufacturing techniques, data, designs or concepts developed by Licensors, covering the gene for cystic fibrosis and uses thereof as covered by the claims of U.S. Patents entitled Cystic Fibrosis Gene.